More than 70,000 product liability lawsuits filed by Zantac users diagnosed with various types of cancer

Event News

Picture of Researcher: Ariana Arce​

Researcher: Ariana Arce​

a.arce@legalhelpadvisor.com

Picture of Journalist: Aaron Vivanco

Journalist: Aaron Vivanco

a.vivanco@legalhelpadvisor.com

Picture of Editor: Daniela Polo

Editor: Daniela Polo

d.polo@legalhelpadvisor.com

Contact Us

We will review your case so that we can help you become a part of the lawsuit to hold the company accountable.

More than 70,000 product liability lawsuits filed by Zantac users diagnosed with various types of cancer

The first Zantac trial in the state will begin on October 10, 2022, according to California Superior Court Judge Evelio Grillo in Alameda Country. There are currently more than 70,000 product liability lawsuits filed by former Zantac users diagnosed with various types of cancer. These lawsuits were filed in Federal and State Courts nationwide, consolidated before the judicial council coordinated proceedings. Furthermore, the second case is scheduled to start in early 2023. Although the judgment of the early trials will not bind on future claimants, they are expected to have a significant impact on the number of Zantac settlements.

Zantac lawsuits have also been filed in the following state jurisdictions:

• California

• Florida

• Illinois (Cook County)

• Minnesota (Minneapolis)

• New Jersey

• New York

• Oregon (Portland)

Plaintiffs present claims against Sanofi, Glaxo SmithKline, Boehringer Ingelheim, and other manufacturers, distributors, and retailers. Alleging information about the risk associated with ranitidine was known.

Nevertheless, Zantac was marketed as a safe and effective treatment for decades. Merely three years after its release, it became the first drug in the U.S. to generate $1 billion in sales. Over-the-counter sales alone totaled $129 million in 2018.

Tests Find Cancer-Causing NDMA in Samples of Zantac:

● In June 2019, the Valisure Laboratory found that a single tablet of Zantac contained 26,000 times the acceptable daily limit of NDMA.

● On April 1, 2020, the administration proposed the removal of all Zantac and generic ranitidine from the market. The U.S. food and drug administration had been warning consumers and doctors about the drug for months.

● In October 2020, Zantac manufacturer, Sanofi, recalled Zantac. Samples were found to contain unsafe levels of N-Nitrosodimethylamine (NDMA), a cancer-causing substance.

● In early 2021, an independent laboratory reported that time and exposure to high levels of heat increase the levels of NDMA in ranitidine.

The evidence is clear that Zantac causes different types of cancer. There is no debate within the scientific and medical community that NDMA is a substance that causes cancer in humans and animals.